Who
John Cox
CEO & President
Company insider
Files Form 4 as: CEO & President, Dyne Therapeutics; Director, Sigilon Therapeutics; Director, Repligen; Chief Executive Officer, Bioverativ; EVP Pharmaceutical Oper & Tech, Biogen.
In numbers
- Trades disclosed
- 218
- Buys
- 2
- Sells
- 24
- Bought
- $2.0M
- Sold
- $15.7M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 28 Oct 2010
- Last trade
- 8 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K5,658 at $18.88 | filing |
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K5,658 at $18.88 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $131K4,986 at $26.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $131K4,986 at $26.28 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K2,683 at $18.33 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K2,683 at $18.33 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $61K3,311 at $18.36 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $61K3,311 at $18.36 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,732 at $14.90 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,732 at $14.90 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 5 Dec 2025filed 5 Dec 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $55K2,662 at $20.72 | filing |
| 5 Sep 2025filed 9 Sep 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K2,640 at $13.41 | filing |
| 16 Jul 2025filed 18 Jul 2025 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,285 at $0.00 | filing |
| 15 Jul 2025filed 15 Jul 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 15 Jul 2025filed 15 Jul 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 15 Jul 2025filed 15 Jul 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
News
John Cox wants business owners to stop waiting until it's too lateazbigmedia.com · 8 Oct 2026
1 headline in the last 90 days name John Cox; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.